Literature DB >> 11817989

Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making.

C Daniel Mullins1, Junling Wang.   

Abstract

Previous research indicates that in order to make pharmacoeconomic information applicable and useful for pharmaceutical benefit management (PBM) companies, several aspects need to be considered and improved. These include: timely availability of information, head-to-head comparators, peer-reviewed publications, independent sponsorship of pharmacoeconomic studies, use of relevant populations in research and published pharmacoeconomic models, and pharmacoeconomics training for pharmaceutical companies' sales personnel. In addition to these measures, guidelines have been playing an important role in improving the applicability of pharmacoeconomic information. This paper examines the progress to date in enhancing the applicability of pharmacoeconomics for optimal PBM decision making. The greatest improvements have been made in enhancing the quality of pharmacoeconomic research and the quality of peer-reviewed publications. Direct comparator studies are starting to emerge, but in limited numbers. The need for additional training of pharmaceutical representatives and PBM staff members remains a critical issue.

Mesh:

Substances:

Year:  2002        PMID: 11817989     DOI: 10.2165/00019053-200220010-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  37 in total

1.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology.

Authors:  M Friedberg; B Saffran; T J Stinson; W Nelson; C L Bennett
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

2.  Pharmacoeconomics research credibility: a controversial and recurring theme in health outcomes research.

Authors:  M E Minshall; M C Kody; F Mosbacher
Journal:  Med Care       Date:  1999-04       Impact factor: 2.983

3.  Applications of modelling studies.

Authors:  M J Nuijten; J Starzewski
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

4.  Pharmacoeconomics and the formulary decision-making process.

Authors:  A Bakst
Journal:  Hosp Formul       Date:  1995-01

5.  Panel 4: education and skills needed to conduct, interpret, and use economic evaluations in healthcare.

Authors:  K Copley-Merriman; G Vanscoy
Journal:  Value Health       Date:  1999 Mar-Apr       Impact factor: 5.725

6.  American Academy of Dermatology guidelines of care. Development and process.

Authors:  L A Drake; K P Yale; B J Lowery; A L Dunbar; R Gillies
Journal:  Arch Dermatol       Date:  1997-11

7.  Making economic evaluations respectable.

Authors:  U E Reinhardt
Journal:  Soc Sci Med       Date:  1997-08       Impact factor: 4.634

8.  The role of pharmacoeconomics in disease management. A pharmaceutical benefit management company perspective.

Authors:  N Thomas
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

9.  Pharmacoeconomics and outcomes research.

Authors:  J L Bootman
Journal:  Am J Health Syst Pharm       Date:  1995-07-15       Impact factor: 2.637

10.  Understanding financial conflicts of interest.

Authors:  D F Thompson
Journal:  N Engl J Med       Date:  1993-08-19       Impact factor: 91.245

View more
  3 in total

1.  The role of pharmacoeconomics in formulary decision making in different hospitals in Riyadh, Saudi Arabia.

Authors:  Mohammed S Alsultan
Journal:  Saudi Pharm J       Date:  2010-11-04       Impact factor: 4.330

2.  Improving confidence in observational studies : should statistical analysis plans be made publicly available?

Authors:  Eberechukwu Onukwugha
Journal:  Pharmacoeconomics       Date:  2013-03       Impact factor: 4.981

3.  The role of economic evaluation in the decision-making process of family physicians: design and methods of a qualitative embedded multiple-case study.

Authors:  Chantale Lessard; André-Pierre Contandriopoulos; Marie-Dominique Beaulieu
Journal:  BMC Fam Pract       Date:  2009-02-11       Impact factor: 2.497

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.